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Background
Human African trypanosomiasis (HAT), or sleeping sickness, is a disease caused by 2 subspe-
cies of the protozoan parasite, Trypanosoma brucei (T. b.): T. b. gambiense and T. b. rhode-
siense. T. b. gambiense causes the chronic form of sleeping sickness in West and Central Africa,
and it is responsible for 98% of all reported cases [1]. T. b. rhodesiense causes an acute, rapidly
progressive infection in Eastern and Southern Africa. Over the last decade, control measures
have reduced HAT incidence to less than 3,000 reported cases in 2015, the lowest level in 75
years [2]. The target of the World Health Organization (WHO) is the elimination of the disease
as a public health problem by 2020 and interruption of its transmission by 2030 [1].
HAT has been considered as an invariably fatal disease. However, recent studies indicate
that this is not the case [3–5]. Infection by T. b. gambiense can result in a wide range of clinical
outcomes in its human host [3–5]. This has been illustrated by the descriptions of self-cure in
HAT patients refusing treatment in Ivory Coast [6] and the report of a patient who developed
sleeping sickness in the United Kingdom 29 years after he last left an endemic area [7]. Fur-
thermore, individuals with an elevated response to the card agglutination test for trypanosomi-
asis (CATT) and positive to the specific T.b. gambiense immune trypanolysis test, but who
remain negative to available microscopic parasitological tests for more than 2 years, have been
reported in West Africa and are believed to harbor latent infections [8,9]. These observations
suggest that individuals infected with T. b. gambiense may exhibit variable degrees of suscepti-
bility, and some may be able to control the infection over long periods of time, as has also been
demonstrated for African Animal Trypanosomiasis (AAT), caused by T. congolense [10,11].
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The TrypanoGEN network is composed of researchers from Burkina Faso, Cameroon,
Coˆte d’Ivoire, Guinea, Democratic Republic of Congo (DRC), Malawi, Uganda, Zambia,
France, the UK, and Belgium and is aimed at understanding the genetic basis of human sus-
ceptibility to trypanosomiasis. The TrypanoGEN network is a member of the Human Heredity
and Health in Africa (H3Africa www.h3africa.org) Consortium, which is an initiative funded
and supported by the Wellcome Trust (UK) and the National Institutes of Health (United
States). Members of the H3Africa Consortium are undertaking genome-wide association stud-
ies (GWAS) on a wide range of communicable and noncommunicable diseases. H3Africa
members are committed to making all specimens and data available to other researchers [12].
The objectives of the TrypanoGEN network are to identify the human genetic determinants
of disease susceptibility/resistance in different African populations and to determine if these
are shared for the 2 diseases caused by the different trypanosome subspecies. To address these
scientific questions, the TrypanoGEN project has created a biobank of specimens with stan-
dardized parasitological and clinical data. HAT is a disease of rural Africa, often in areas with
limited health resources and impoverished populations. The diagnosis of trypanosomiasis, and
particularly of subclinical cases, requires multiple tests in both the field and the laboratory.
Large specimen collections from cases and individuals with latent infections require large sur-
veys in areas that are remote from research laboratories. Both these factors make it hard to
obtain large numbers of well-phenotyped specimens. To date, all the genetic association stud-
ies on the susceptibility in HAT have been performed on limited numbers of specimens sam-
pled in single countries [13–16]. Thus, the TrypanoGEN biobank is an important resource
to enable the first GWAS of HAT using a large and well-characterized specimen collection
originating from different populations. A GWAS will make it possible to identify genetic deter-
minants of susceptibility/resistance, validate hypotheses developed in the laboratory, and facil-
itate the development or evaluation of new diagnostic tests.
In this article, we describe the TrypanoGEN network biobank for human African trypano-
somiasis, where all specimens used in our research are archived and made available to other
researchers. Another biobank of specimens from HAT patients and endemic controls has been
established previously by the WHO, but this is exclusively for the development of HAT diag-
nostic tests, and specimens are not available for genetic research [17].
What are the characteristics and requirements of the HAT biobank?
What ethical approval was obtained?
Ethical approval was provided by the national ethics councils of each of the TrypanoGEN par-
ticipating countries: Cameroon (2013/364/L/CNERSH/SP), Democratic Republic of Congo
(No 1/2013), Guinea (1-22/04/2013), Cote d’Ivoıˆre (2014/No 38/MSLS/CNER-dkn), Malawi
(1213), Uganda (HS 1344), and Zambia (011-09-13). Information (in English or French and
several local languages) was provided to the participants through community engagement
with potential participants and community leaders at every field visit. This information
included the scientific objectives of the TrypanoGEN network. The participants were guided
through the consent forms, and written consent was obtained to collect biological specimens.
This consent represents a broad consent that allows for genomic investigations as part of the
TrypanoGEN network. Genetic studies on HAT by other researchers are allowed but require
approval from the institutional review boards of the country that supplied the specimens.
From whom were specimens collected?
Study participants were classified into 3 groups depending on the serological and parasitologi-
cal results:
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• Cases, defined as individuals with trypanosomes detected in either lymph node aspirate,
blood, or cerebrospinal fluid (CSF) by microscopy, after concentrating parasites, if necessary
[18–21].
• Individuals with latent infections, with positive CATT [22] and trypanolysis test results [23],
in whom no trypanosomes were detected by microscopy for at least 2 years.
• Controls, defined as individuals living in an endemic area who were CATT and trypanolysis
negative, with no signs or symptoms suggestive of HAT and without evidence of previous
HAT infection. The control participants had similar age and gender distributions as the case
participants (Fig 1).
In total, the TrypanoGEN biobank currently includes 1,345 cases, 179 individuals with
latent infections, and 1,777 controls (Table 1).
How were specimens collected?
Specimens for the biobank were generally collected during field surveys in collaboration with
national control programs in 3 different ways:
• Previously archived specimens: existing collections of previously archived specimens were
centralized into their respective network node. For previously archived specimens, all indi-
viduals were revisited to obtain consent.
• Retrospectively collected specimens: study sites were revisited to consent and resample pre-
viously diagnosed and treated patients and individuals with latent infections.
Fig 1. Age frequencies of case and control participants. Many participants did not know their age, and
approximate ages were assigned to many subjects, leading to large spikes of numbers at 30, 40, 50, and 60
years, with minor spikes at 5-year intervals. These spikes were smoothed using a moving-window average over
10 years. The mean ages of Trypanosoma brucei gambiense and T. b. rhodesiense case and control participants
were 36 and 42, respectively. The age distributions were similar except that the T. b. rhodesiense subjects’ ages
were shifted to the right.
https://doi.org/10.1371/journal.pntd.0005438.g001
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• Prospectively collected specimens: HAT case patients before treatment and individuals with
latent infections were identified as part of active surveillance surveys performed by the spoke
teams in collaboration with their respective National Control Programs (NCP).
Whole blood, plasma, and buffy coat (BC) were collected from each study participant fol-
lowing good clinical practice principles. The specimens were frozen in the field at −20˚C
before final storage at −80˚C.
Epidemiological and laboratory data were recorded and linked to biological specimens
(Table 2). Plasma was used to perform the trypanolysis test. Blood or BC was used for DNA
extractions using the Whole Blood Midikit from Qiagen. DNA was quantified by fluorometric
Qubit assay (Invitrogen) or Nanodrop spectrophotometer.
Where were specimens collected and stored?
The biobank stores plasma and DNA from blood in 3 hubs that are responsible for specimen
management and associated data, including reception, control, processing, storage, and subse-
quent distribution to end users. Shipment from intermediate national storage to the central
hubs was by express courier on dry ice.
A map of the TrypanoGEN network is given in Fig 2. Specimens are held at the following
locations:
• The College of Veterinary Medicine, Animal Resources & Bio-security (COVAB), Makerere
University, Kampala, Uganda. This location preserves specimens from the T. b. gambiense–
endemic districts of northwestern Uganda and the T. b. rhodesiense–endemic districts of
Table 1. Number of individuals by country with test results that meet the criteria for specimen classification.
Country Cases Latent Infections Controls
Trypanosoma brucei gambiense
Guinea 346 89 193
Ivory Coast 123 18 271
Democratic Republic of the Congo 213 72 282
Cameroon 56 - 160
Uganda 157 - 227
T. b. rhodesiense
Uganda 245 - 372
Malawi 162 - 200
Zambia 39 - 62
Total 1,345 179 1,777
https://doi.org/10.1371/journal.pntd.0005438.t001
Table 2. Metadata associated with each specimen in the database.
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eastern Uganda as well as from the Rumphi and Nkhotakota foci in Malawi and multiple dis-
tricts of Zambia.
• Centre International de Recherche-De´veloppement sur l’Elevage en zone Subhumide (CIR-
DES), Burkina Faso, which holds specimens from Fore´cariah, Dubre´ka, and Boffa foci col-
lected by the National Control Programme of Guinea and from Bonon and Sinfra foci in
Coˆte d’Ivoire, collected by the Universite´ Jean Lorougnon Gue´de´, Daloa, Coˆte d’Ivoire.
• Institut National de Recherche Biomedicale (INRB), Kinshasa, DRC, holds specimens from
Bandundu, DRC, and from the Campo and Bipindi foci in Cameroon, collected by the Fac-
ulty of Science, University of Dschang, Cameroon.
What metadata are associated with specimens?
Metadata associated with each specimen are shown in Table 2. Phenotyping was focused solely
on HAT; no screening was done for other infections. Whole genome sequencing to 10X
Fig 2. Map showing countries from which samples were collected and the proportion of each type of subject in
the collection. Stars indicate locations of biobank hubs.
https://doi.org/10.1371/journal.pntd.0005438.g002
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coverage has been performed on 298 DNA specimens from 6 countries. Case patients, individ-
uals with latent infections, and control individuals will be genotyped using the H3Africa 2.5
million single nucleotide polymorphism (SNP) chip genotyping assay [12]. The sequence data
and SNP chip data will be associated with the subjects and made freely available under the
standard H3Africa data release policy 1 year after data collection is completed. Guidelines and
information on the policies for specimens and data sharing are accessible through the
H3Africa website (www.h3africa.org) [12].
How can users access the TrypanoGEN biobank?
The specimens are accessible to the members of the network for further research on HAT after
review of applications by the sample access committee and are subject to a material transfer
agreement. Interested researchers from outside the TrypanoGEN network should request
access to the biobank through the principle investigators (PIs) of the 3 hubs, who will refer
requests to the TrypanoGEN sample access committee so that they can find if there are speci-
mens available that meet the needs. Contact details of the PIs are available from the project
website: www.trypanogen.net.
The TrypanoGEN biobank database is web accessible and allows the user to browse and fil-
ter TrypanoGEN subjects to identify sets of subjects that might be appropriate for a particular
study. Access to the database is available on request to the PIs of the hubs. Access will be pro-
vided to researchers to evaluate the utility of the specimens for their purpose and make specific
requests for specimen sets.
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Key learning points
• The rapidly declining cost of genetic assays means that specimen collection is now the
most expensive, laborious, and time-consuming part of genetic research. The biobank
will share this valuable resource to facilitate studies that would not otherwise be
possible.
• The H3Africa Consortium members are setting up biobanks for specimens associated
with a wide range of conditions. This is an opportune moment to set up collaborations
with research questions cutting across regions.
• Experimental reproducibility is a hot current topic [24]. The availability of a large stan-
dard set of specimens from multiple populations will allow researchers to undertake
well-powered experiments that can reveal both population-specific and Africa-wide
associations with trypanosomiasis that can be tested for reproducibility by other
researchers.
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